Sintilimab plus IBI305 for hepatocellular carcinoma

Luo Cheng¹, Heng Xiao²

Affiliations

¹ Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
² Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China. Electronic address: xiaohengdoctor@126.com.

PMID: 34478671
DOI: 10.1016/S1470-2045(21)00424-1

Comment

Sintilimab plus IBI305 for hepatocellular carcinoma

Luo Cheng et al. Lancet Oncol. 2021 Sep.

. 2021 Sep;22(9):e387.

doi: 10.1016/S1470-2045(21)00424-1.

Authors

Luo Cheng¹, Heng Xiao²

Affiliations

¹ Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
² Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China. Electronic address: xiaohengdoctor@126.com.

PMID: 34478671
DOI: 10.1016/S1470-2045(21)00424-1

No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests.

Comment in

Sintilimab plus IBI305 for hepatocellular carcinoma - Author's reply.
Fan J. Fan J. Lancet Oncol. 2021 Sep;22(9):e388. doi: 10.1016/S1470-2045(21)00479-4. Lancet Oncol. 2021. PMID: 34478672 No abstract available.

Comment on

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, Chen Z, Liu B, Jia W, Wu J, Wang J, Shao G, Zhang B, Shan Y, Meng Z, Wu J, Gu S, Yang W, Liu C, Shi X, Gao Z, Yin T, Cui J, Huang M, Xing B, Mao Y, Teng G, Qin Y, Wang J, Xia F, Yin G, Yang Y, Chen M, Wang Y, Zhou H, Fan J; ORIENT-32 study group. Ren Z, et al. Lancet Oncol. 2021 Jul;22(7):977-990. doi: 10.1016/S1470-2045(21)00252-7. Epub 2021 Jun 15. Lancet Oncol. 2021. PMID: 34143971 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Sintilimab plus IBI305 for hepatocellular carcinoma

Affiliations

Sintilimab plus IBI305 for hepatocellular carcinoma

Authors

Affiliations

Conflict of interest statement

Comment in

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical